Allegations of fraud and false advertising by the Federal Trade Commission and New York Attorney General Eric Schneiderman against the makers of a dietary supplement that claimed to improve memory function were dismissed in federal court Thursday.
U.S. District Judge Louis Stanton of the Southern District of New York granted the motions to dismiss in Federal Trade Commission v. Quincy Bioscience Holding Co., 17-cv-00124, by Quincy Bioscience, the maker of Prevagen, and its co-founders, Mark Underwood and Michael Beaman.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
